PharMerica (PMC) Tops Q3 EPS by 16c; Guides In-Line
More News related to PMC
- PharMerica Names Geoffrey G. Meyers to Its Board of Directors
- UBS Starts Numerous Healthcare Stocks: CAH, MCK, ESRX at Buy, PMC, OCR at Neutral
- PharMerica to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- PharMerica to Present at the Credit Suisse 18th Annual Healthcare Conference
- PharMerica to Present at the Oppenheimer 20th Annual Healthcare Conference
PharMerica Corporation (NYSE: PMC) reports Q3 EPS of $0.48, 16 cents better than the analyst estimate of $0.32. Revenue for the quarter was $461 million, which compares to the estimate of $461.38 million.
PharMerica sees FY EPS of $1.23-$1.32, versus the consensus of $1.28.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
